2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.06 Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC

P4.11E.06 Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC

Back to course

Pdf Summary

The study investigated the effectiveness and safety of using envafolimab in combination with recombinant human endostatin (Rh-endostatin) and chemotherapy as a first-line treatment for patients with advanced squamous non-small cell lung cancer (sq-NSCLC). Envafolimab, notable for being the first approved single-domain anti-PD-L1 antibody, can be administered conveniently through a subcutaneous injection. Previous studies have shown that Rh-endostatin can extend survival in sq-NSCLC patients without added hemorrhage risk.<br /><br />Conducted as a prospective, single-arm, multicenter phase II study, it recruited 26 patients between December 2021 and January 2024, with 24 being evaluated for safety and 21 for efficacy. Patients were eligible if they were between 18-75 years with confirmed locally advanced, metastatic, or recurrent sq-NSCLC, an ECOG performance status of 0-1, and had not undergone prior systemic therapy.<br /><br />Patients underwent 4-6 cycles of chemotherapy (Paclitaxel/nab-paclitaxel, cisplatin/carboplatin) with envafolimab and Rh-endostatin, followed by maintenance treatment with envafolimab. The primary endpoint of the study was to measure 1-year progression-free survival (PFS), and secondary endpoints included overall response rate (ORR), duration of response (DOR), PFS, overall survival (OS), and safety.<br /><br />Results indicated a favorable ORR of 81% and disease control rate (DCR) of 100%. While overall survival data were not yet mature, the safety profile was considered tolerable. Treatment-emergent adverse events (TEAEs) were reported in 95.8% of patients, mainly related to chemotherapy, while immune-related adverse events (irAEs) affected 45.8%, with rash being the most common.<br /><br />The study concluded that combining envafolimab with Rh-endostatin and chemotherapy demonstrates promising efficacy for treating advanced sq-NSCLC with an acceptable safety profile.

Asset Subtitle

Lian Liu

Meta Tag

Speaker Lian Liu

Topic Metastatic NSCLC – Immunotherapy

Keywords

envafolimab

recombinant human endostatin

chemotherapy

squamous non-small cell lung cancer

sq-NSCLC

single-domain anti-PD-L1 antibody

subcutaneous injection

progression-free survival

overall response rate

immune-related adverse events